Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort

Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 treated with sotrovimab between October 2021 and December 2021. Results: We included 32 patients. The main immunocompromising conditions were solid organ transplantation (46.9%) and hematological malignancy (37.5%). Seven patients (21.9%) had respiratory progression: 12.5% died and 9.4% required mechanical ventilation. Patients treated within the first 14 days of their symptoms had a lower progression rate: 12.0% vs. 57.1%, p = 0.029. No adverse event was attributed to sotrovimab. Conclusions: Sotrovimab was safe and may be effective in its use for immunocompromised patients with severe COVID-19. More studies are needed to confirm these preliminary data.

[1]  S. Gamblin,et al.  WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed , 2022, The Lancet.

[2]  William T. Harvey,et al.  SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies , 2022, Nature Reviews Microbiology.

[3]  B. Amani,et al.  Efficacy and safety of sotrovimab in patients with COVID‐19: A rapid review and meta‐analysis , 2022, Reviews in medical virology.

[4]  S. Tulledge-Scheitel,et al.  Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch , 2022, Open forum infectious diseases.

[5]  L. Pagano,et al.  Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey , 2022, Blood.

[6]  D. Lauffenburger,et al.  A multifaceted high-throughput assay for probing antigen-specific antibody-mediated primary monocyte phagocytosis and downstream functions. , 2022, Journal of immunological methods.

[7]  M. Zazzi,et al.  Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 , 2022, Viruses.

[8]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[9]  Jumpei Ito,et al.  Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies , 2022, The Lancet Infectious Diseases.

[10]  A. Cathcart,et al.  Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2022, JAMA.

[11]  Mark M. Davis,et al.  KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19 , 2022, Science.

[12]  Matthew R. Neville,et al.  Low antispike antibody levels correlate with poor outcomes in COVID‐19 breakthrough hospitalizations , 2022, Journal of internal medicine.

[13]  Ying Luo,et al.  Meta-analysis of immunologic response after COVID-19 mRNA vaccination in solid organ transplant recipients , 2022, Journal of Infection.

[14]  Shinji Watanabe,et al.  Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant , 2022, The New England journal of medicine.

[15]  C. Díaz-Pedroche,et al.  Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study , 2022, Clinical Infection in Practice.

[16]  N. Berger,et al.  COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research , 2022, Blood Reviews.

[17]  Inyoul Y. Lee,et al.  Multiple early factors anticipate post-acute COVID-19 sequelae , 2022, Cell.

[18]  M. Landray,et al.  Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[19]  Qulu Zheng,et al.  Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. , 2021, JAMA internal medicine.

[20]  V. Cuervas-Mons,et al.  Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry , 2021, International Journal of Infectious Diseases.

[21]  Rachel A. Bender Ignacio,et al.  Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19 , 2021, The Lancet Infectious Diseases.

[22]  Rebecca M. Baker,et al.  Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial , 2021, The Lancet Infectious Diseases.

[23]  L. Pagano,et al.  COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA , 2021, Blood.

[24]  John D. Davis,et al.  Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19 , 2021, medRxiv.

[25]  S. Tulledge-Scheitel,et al.  Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities , 2021, medRxiv.

[26]  R. Gibbs,et al.  Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections , 2021, BMC Medicine.

[27]  Mark M. Davis,et al.  Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19 , 2021, Nature Biotechnology.

[28]  M. López-Dosil,et al.  Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  J. Díez-Manglano,et al.  In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain , 2021, PloS one.

[30]  P. Shah,et al.  Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients , 2021, Transplantation.

[31]  D. Skovronsky,et al.  Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 , 2021, The New England journal of medicine.

[32]  E. Orenbuch-Harroch,et al.  BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel , 2021, Clinical Microbiology and Infection.

[33]  Paul J. Hoover,et al.  Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions , 2021, Cell Reports Medicine.

[34]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[35]  James D. Allen,et al.  Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection , 2021, Cell.

[36]  D. Ho,et al.  Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.

[37]  Samuel M. Brown,et al.  A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 , 2020, The New England Journal of Medicine.

[38]  A. Hayward,et al.  A rapid review and meta-analysis of the asymptomatic proportion of PCR-confirmed SARS-CoV-2 infections in community settings , 2020, Wellcome Open Research.

[39]  Mark M. Davis,et al.  Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19 , 2020, Cell.

[40]  G. Guyatt,et al.  A living WHO guideline on drugs for covid-19 , 2020, BMJ.

[41]  Recovery Collaborative Group.  Lopinavir-Ritonavir in Hospitalised Patients with COVID-19: Preliminary Report from a Randomised, Controlled, Open-Label, Platform Trial , 2020, SSRN Electronic Journal.

[42]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[43]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.